Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 351 - 400 out of 17,226

Document Document Title
WO/2017/041403A1
The present invention provides a fluorescent probe substrate for determining an activity of dipeptidyl peptidase IV (DPP-IV) and a use thereof. The probe substrate is a C-4 amide derivative of naphthalimides, GPAN, and can be used to det...  
WO/2017/041733A1
Provided is a polypeptide that inhibits Aβ protein aggregation of Alzheimer's disease, and an amino acid sequence thereof is Xaa1-Xaa2-Xaa3-Xaa4. Xaa1 and Xaa3 are identical amino acids and selected from I, V or L, Xaa2 is selected from...  
WO/2017/040976A1
Disclosed are methods and compositions for selectively targeting sites of traumatic brain injury (TBI). A brain injury-specific 4-amino acid peptide (sequence CAQK), identified by in vivo phage display screening in mice with acute brain ...  
WO/2017/040304A1
Provided herein are compounds of Formula (I) and pharmaceutical compositions thereof, which may be useful as MALT1 inhibitors. Also provided are for the treatment of proliferative disorders (e.g., cancer (e.g., non-Hodgkin' s lymphoma, d...  
WO/2017/039726A1
Disclosed herein are novel HDAC inhibitors. The HDAC inhibitors may be used in methods of treating cancer. The HDAC inhibitors may be used in methods of treating a neurological disorder.  
WO/2017/033055A1
The present invention relates to novel cyclic peptidomimetics, pharmaceutical compositions containing them and their use in the treatment of diseases associated with angiogenesis especially tumors and chronic inflammation in psoriasis, d...  
WO/2017/032487A1
The present invention relates to compounds such as peptides which act as proteasome inhibitors. The compounds are covalently linked with a signal emitting compound or a precursor thereof, via an ester such as a sulfonic ester group for i...  
WO/2017/030814A1
The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by ...  
WO/2017/027967A1
The present application relates to a-substituted amino acid compounds of the Formula (I), compositions comprising these compounds and their use, in particular for the treatment of diseases, disorders or conditions characterized by or ass...  
WO/2017/031209A1
The present disclosure relates to tubulysin derivatives and methods for making the same. The disclosure also relates to the use of such tubulysin derivatives in the preparation of drug conjugates of tubulysins.  
WO/2017/025802A1
Pharmaceutical compositions and methods of their use are provided for reducing inflammation in a subject, blocking leukocyte recruitment, inhibiting tumor metastasis, treating sepsis and preventing/reducing acute kidney injury.  
WO/2017/021004A1
The present invention relates to chromogenic and fluorogenic substrates that can be used for the highly sensitive and selective detection of the activity of serine proteases. The present invention further relates to methods for the detec...  
WO/2017/021904A1
The present invention relates to daclatasvir free base, processes for its preparation, a process for its conversion into pharmaceutically acceptable salts of daclatasvir. The present invention also relates to a process for the preparatio...  
WO/2017/023907A1
The present disclosure relates to phenyl urea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor (FPR), such as agonism o...  
WO/2017/017445A1
The invention relates to peptoids, derivatives and analogues thereof, and to methods of chemically synthesising such compounds. The invention relates to mixed peptoids, derivatives and analogues thereof comprising lysine and arginine typ...  
WO/2017/013660A1
The present invention discloses a peptide capable of stabilizing mutation-induced GBE1 protein destabilization, conjugates comprising same and uses thereof for the treatment of diseases and disorders associate with glycogen storage.  
WO/2016/193954A3
The present invention describes the discovery of the genes that direct the biosynthetic pathway of leupeptin, a potent protease inhibitor of the type of small peptide aldehyde (SPA). The prediction of genes that direct the biosynthesis o...  
WO/2017/013172A1
The invention relates to inhibitors for p-glycoprotein, being compounds that comprise or consist of a tripeptide represented by the sequence XAB, wherein X, A, and B are 7amino acids, wherein X can be any amino acid and A and B are basic...  
WO/2017/011812A1
The present specification discloses modified APY cyclic peptides having EphA4 antagonistic activity, pharmaceutical compositions containing such EphA4 antagonists, and methods and uses of treating an EphA4-based disease, disorder or path...  
WO/2016/196124A3
The present invention relates to novel prodrugs of primary or secondary amine-comprising biologically active moieties and pharmaceutically acceptable salts thereof, prodrug reagents, pharmaceutical compositions comprising said prodrugs a...  
WO/2017/011826A1
Anti-lymphoma plant virus particles are described. The anti-lymphoma plant virus particles include a filamentous or rod-shaped plant virus particle linked to an antimitotic agent. A therapeutically effective amount of an anti-lymphoma pl...  
WO/2017/011582A1
The present disclosure provides assays for lysosomal enzymes, specifically palmitoyl protein thioesterase 1 (PPT1) and tripeptidyl peptidase 1 (TPP1), using, for example, tandem mass spectrometry. The assays involve the detection of enzy...  
WO/2017/005902A1
The present disclosure relates to methods of preparing and crystallizing β-turn cyclic peptidomimetic salts of formula (I): where R1, R2, R3, R4, R5, R6, R7, R8, R10, X, Y and n are as defined in the specification. The present disclosur...  
WO/2017/004811A1
Provided in the application are an active peptide for inhibiting an AMPA receptor and a preparation method and the use thereof. The preparation method for the active peptide comprises the following steps: 1) salmon skin is soaked and the...  
WO/2017/005547A1
The invention relates to a method for producing 2,6-bis(methionyl)-1,4-diketopiperazine comprising the following steps: a) heating a reaction mixture containing methionine and a polar protic solvent at a temperature of 145.0 to 169.5 °C...  
WO/2017/004396A1
A chewable delivery system for GSH comprised of a gum base and reduced glutathione, to supplement GSH during acute GSH depletion, and useful during acute GSH depletion produced by alcohol ingestion, and intense exercise. The blood alcoho...  
WO/2017/002765A1
Provided are: a calorie-reducing composition including a cyclic dipeptide or a salt thereof; and a food or beverage including said calorie-reducing composition. The cyclic dipeptide included in this calorie-reducing composition is effici...  
WO/2017/002895A1
Provided is a composition which has high absorbability in vivo and excellent biological safety, and which can enhance the angiotensin-converting enzyme inhibitory activity induced by amino acids. The ratio in the composition of the tot...  
WO/2016/206138A1
Provided are a compound for inhibiting a histone deacetylase (HDAC) and preparation method and use thereof. Provided is a compound represented by the following general formula, wherein a substituent group is defined as in the specificati...  
WO/2016/210294A1
Thienopyrrole compounds that may inhibit Oplophorus -derived luciferases are disclosed, as well as compositions and kits comprising the thienopyrrole compounds, and methods of using the thienopyrrole compounds.  
WO/2016/181408A3
The present invention relates to novel short-chain peptides of the general formula (I), which are selective and peripherally acting KOR agonist, their tautomeric forms, their enantiomers, their diastereoisomers, their stereoisomers, thei...  
WO/2016/205791A2
A body-weight support harness system is disclosed, including an improved body weight support system and method.  
WO/2016/204197A1
Provided are: a protein degradation inducing tag which is a molecule that has affinity with proteases and does not inhibit degradation of a protein by proteases; a protein degradation inducing molecule that is a conjugate of at least one...  
WO/2016/197190A1
In one aspect, the present invention relates to the crystal structure of Plasmodium vivax plasmepsin V in complex with an inhibitor, and to methods of using the crystal structure and related structural information to identify, design and...  
WO/2016/192149A1
A class of bis-alkoxyl amide alkyl cationic peptide lipids has a chemical structural formula: . After the bis-alkoxyl amide alkyl cationic peptide lipids are dispersed in water, a cationic peptide liposome that has desirable stability, u...  
WO/2016/193990A1
The application relates to peptide-based compounds of Formula I such as the compound of Formula II, methods of making such compounds, gels comprising such compounds, methods of making gels, methods of using such compounds for containing ...  
WO/2016/193514A1
The invention relates to compounds derived from the bacterial wall of Staphylococcus aureus for use as haptens, to applications and methods thereof for detecting S. aureus, and to the antibodies and antisera generated for use.  
WO/2016/196243A1
Tetrapeptide linkers for reversibly linking a first compound to a amine-containing second compound are described. Compounds containing the tetrapeptide linkers and methods of using the tetrapeptide linkers are also described.  
WO/2016/192150A1
A class of propyl cationic peptide lipids is propyl cationic peptide lipid compounds having a general formula structure as follows. After the propyl cationic peptide lipids are dispersed in water, a cationic liposome with a particle size...  
WO/2016/195070A1
Provided are: a method for efficiently and steadily producing a reduced glutathione α-form crystal having both excellent quality and excellent productivity; and a method for storing the crystal. The present invention relates to: a metho...  
WO/2016/188711A1
The present invention relates to a novel and improved process for the preparation of the compound 2-{4-[2-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulfan yl)-3,5-dicyano-6-(pyrrolidin-1-yl)-pyridin-4-yl]-phenoxy}-e thyl-L-alanyl-L-a...  
WO/2016/185200A1
The invention provides a compound which is a peptide derivative of formula (1) as defined in the claims or a salt thereof: RG is H, -CH2-RGA or C1-12 hydrocarbyl optionally substituted with 1 to 4 substituents selected from -OR', -NO2, -...  
WO/2016/184432A1
Disclosed is a tyramine derivative compound, as shown in formula (I). Also disclosed are a pharmaceutical composition comprising the compound and an application of the pharmaceutical composition in preparing a drug for treating and/or pr...  
WO/2016/182660A1
The invention is directed to peptides which inhibit phosphorylation of an amino phosphoacceptor domain of C/ΕΒΡβ and their use for treating inflammation and fibrosis.  
WO/2016/097957A9
The present invention describes a new peptide aldehyde produced naturally by Streptomyces lividans 66, which we have called livipeptin. Using genome mining of natural products, we predicted that SLl0883-5 genes encode an unprecedented bi...  
WO/2016/180740A1
The present invention provides a process for the production of compound (III) or a deprotected product thereof: comprising reacting compound (II) with chloroacetic acid, in the presence of a reducing agent; wherein PG is a protecting gro...  
WO/2016/178426A1
Disclosed are: an agent having anti-ice nucleation activity containing a complex that is formed of a tyrosine peptide represented by general formula (1) (wherein, X and Y are the same or different, and each represent an amino acid residu...  
WO/2016/179398A1
Isoform-selective lysine deacetylase inhibitors are described. Inhibitors of the lysine deacetylase enzyme are useful as antitumor drugs and for treating addiction, asthma, cardio-vascular disease, immunosuppression, neurodegenerative di...  
WO/2016/170544A1
The present invention relates to process for the preparation of (2S)-N-((S)-l -((S)-4-methyl-1 -((R)-2-methyloxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phen ylethyl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido )-4 -methylpentanami...  
WO/2016/164308A1
Provided herein are de novo binding domain containing polypeptides (DBDpp) that specifically bind a target of interest. Nucleic acids encoding the DBDpp, and vectors and host cells containing the nucleic acids are also provided. Librarie...  

Matches 351 - 400 out of 17,226